Funds and ETFs Aprea Therapeutics, Inc.

Equities

APRE

US03836J2015

Biotechnology & Medical Research

Delayed Nasdaq 04:30:00 2024-03-28 pm EDT 5-day change 1st Jan Change
6.69 USD +10.21% Intraday chart for Aprea Therapeutics, Inc. +5.35% +42.34%
Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing novel synthetic lethality-based cancer therapeutics that target DNA damage response (DDR) pathways. Its synthetic lethality product candidate is ATRN-119, a clinical-stage small molecule inhibitor of ataxia telangiectasia and Rad3-related (ATR), a kinase that plays a critical role in DDR. It is targeting WEE1, a kinase that is a key regulator of multiple phases of the cell cycle. Its lead WEE1 inhibitor product candidate is ATRN-1051. In addition, it has a preclinical research program directed at a second-generation ATR inhibitor, ATRN-354. It is also evaluating combination opportunities within its pipeline, including research on the combination of ATRN-119 and ATRN-1051. Its pipeline includes the clinical-stage asset ATRN-119, an ATR inhibitor that is being evaluated in a Phase 1/2a clinical trial in patients with advanced solid tumors having mutations in defined DDR-related genes.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
6.69 USD
Average target price
15.67 USD
Spread / Average Target
+134.18%
Consensus
  1. Stock
  2. Equities
  3. Stock Aprea Therapeutics, Inc. - Nasdaq
  4. Funds and ETFs Aprea Therapeutics, Inc.